Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?

摘要: Current strategies for immunosuppression in liver transplant (LT) recipients include the design of protocols targeting a more individualized approach to reduce risk factors such as renal failure, cardiovascular complications and malignancies. Renal injury LT may be often multifactorial is associated with increased post-transplant morbidity mortality. The quest low toxicity immunosuppressive regimens has been challenging resulted CNI minimization or withdrawal conversion mycophenolate mofetil (MMF) and/or mammalian target rapamycin inhibitor-based regimens. Use antibody induction delay administration an option particular immunocompromized, critically ill patients high MELD scores. Protocols including MMF introduction concomitant have potential recover function even medium long term after LT. We review on hot topics prevention management acute chronic patients. For this purpose, we present discuss results from studies published current literature presented at recent meetings.